Catabolism of C1 inhibitor influences the response to replacement therapy in hereditary angioedema

Pharmacokinetic data in a patient with poor treatment response to plasma-derived C1 inhibitor compared with 17 control patients suggest that poor treatment response likely depends on increased catabolism, but not through interaction with target proteases.

http://ift.tt/2i3U6PH